These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 20735398)

  • 41. Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma.
    Marcheselli R; Bari A; Tadmor T; Marcheselli L; Cox MC; Papotti R; Ferrari A; Baldini L; Gobbi P; Levy I; Pugliese G; Federico M; Polliack A; Pozzi S; Sacchi S
    Hematol Oncol; 2020 Oct; 38(4):439-445. PubMed ID: 32495944
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
    Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
    Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project.
    Dabaja BS; Vanderplas AM; Crosby-Thompson AL; Abel GA; Czuczman MS; Friedberg JW; Gordon LI; Kaminski M; Niland J; Millenson M; Nademanee AP; Zelenetz A; LaCasce AS; Rodriguez MA
    Cancer; 2015 Apr; 121(7):1032-9. PubMed ID: 25492236
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Cho MC; Chung Y; Jang S; Park CJ; Chi HS; Huh J; Suh C; Shim H
    Medicine (Baltimore); 2018 Nov; 97(45):e13046. PubMed ID: 30407302
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma.
    Aoki K; Takahashi T; Tabata S; Kurata M; Matsushita A; Nagai K; Ishikawa T
    Leuk Lymphoma; 2013 Nov; 54(11):2441-7. PubMed ID: 23452117
    [TBL] [Abstract][Full Text] [Related]  

  • 46. EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru.
    Beltran BE; Castillo JJ; Morales D; de Mendoza FH; Quinones P; Miranda RN; Gallo A; Lopez-Ilasaca M; Butera JN; Sotomayor EM
    Am J Hematol; 2011 Aug; 86(8):663-7. PubMed ID: 21761432
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution.
    Salas MQ; Mercadal S; Domingo Domenech E; Oliveira AC; Encuentra M; Climent F; Andrade Campos M; Aguilera C; Fernández de Sevilla A; Sureda A; González-Barca E
    Leuk Lymphoma; 2020 Mar; 61(3):575-581. PubMed ID: 31684781
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone.
    Chae YS; Shin H; Sohn SK; Lee SJ; Moon JH; Kang BW; Kim JG; Yang DH; Lee JJ; Park TI
    Leuk Lymphoma; 2012 Sep; 53(9):1757-63. PubMed ID: 22372848
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
    Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
    Bartlett NL; Wilson WH; Jung SH; Hsi ED; Maurer MJ; Pederson LD; Polley MC; Pitcher BN; Cheson BD; Kahl BS; Friedberg JW; Staudt LM; Wagner-Johnston ND; Blum KA; Abramson JS; Reddy NM; Winter JN; Chang JE; Gopal AK; Chadburn A; Mathew S; Fisher RI; Richards KL; Schöder H; Zelenetz AD; Leonard JP
    J Clin Oncol; 2019 Jul; 37(21):1790-1799. PubMed ID: 30939090
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study.
    Winter JN; Weller EA; Horning SJ; Krajewska M; Variakojis D; Habermann TM; Fisher RI; Kurtin PJ; Macon WR; Chhanabhai M; Felgar RE; Hsi ED; Medeiros LJ; Weick JK; Reed JC; Gascoyne RD
    Blood; 2006 Jun; 107(11):4207-13. PubMed ID: 16449523
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
    Li X; Huang H; Xu B; Guo H; Lin Y; Ye S; Yi J; Li W; Wu X; Wang W; Zhan H; Xie D; Peng J; Cao Y; Pu X; Guo C; Hong H; Wang Z; Fang X; Zhou Y; Lin S; Liu Q; Lin T
    Cancer Res Treat; 2019 Jul; 51(3):919-932. PubMed ID: 30282447
    [TBL] [Abstract][Full Text] [Related]  

  • 53. DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma.
    Zhang XY; Liang JH; Wang L; Zhu HY; Wu W; Cao L; Fan L; Li JY; Xu W
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):117-127. PubMed ID: 30327941
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MYC protein expression is associated with poor prognosis in diffuse large B cell lymphoma patients treated with RCHOP chemotherapy.
    Zhou M; Wang J; Ouyang J; Xu JY; Chen B; Zhang QG; Zhou RF; Yang YG; Shao XY; Xu Y; Chen YM; Fan XS; Wu HY
    Tumour Biol; 2014 Jul; 35(7):6757-62. PubMed ID: 24719189
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of novel prognostic autoantibodies in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high-throughput antigen microarray.
    Dai L; Chen H; Tan Q; Wang Y; Li L; Lou N; Fan G; Xie T; Luo R; Wang S; Zhou Y; Zhong Q; Yao J; Zhang Z; Tang L; Shi Y; Han X
    Cancer; 2024 Apr; 130(8):1257-1269. PubMed ID: 38133926
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma.
    Hao X; Wei X; Huang F; Wei Y; Zeng H; Xu L; Zhou Q; Feng R
    PLoS One; 2015; 10(5):e0126615. PubMed ID: 25974110
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SIL index, comprising stage, soluble interleukin-2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B-cell lymphoma.
    Tomita N; Sakai R; Fujisawa S; Fujimaki K; Taguchi J; Hashimoto C; Ogawa K; Yamazaki E; Ishigatsubo Y
    Cancer Sci; 2012 Aug; 103(8):1518-23. PubMed ID: 22587388
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical risk scores do not accurately identify a very high risk population with diffuse large B cell lymphoma-an analysis of 386 Portuguese patients.
    Coutinho R; Lobato J; Esteves S; Cabeçadas J; Gomes da Silva M
    Ann Hematol; 2019 Aug; 98(8):1937-1946. PubMed ID: 30949752
    [TBL] [Abstract][Full Text] [Related]  

  • 59. External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival.
    Warnnissorn N; Kanitsap N; Niparuck P; Boonsakan P; Kulalert P; Limvorapitak W; Bhoopat L; Saengboon S; Chantrathammachart P; Puavilai T; Chuncharunee S
    Hematology; 2022 Dec; 27(1):1237-1245. PubMed ID: 36413354
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
    Ferrara F; Ravasio R
    Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.